You just read:

European Medicines Agency Issues Positive Opinion, Recommends Full Approval of IMBRUVICA® (ibrutinib) to Treat Waldenstrom's Macroglobulinemia

News provided by

Pharmacyclics, Inc.

May 22, 2015, 08:04 ET